The case for & against
Bull & Bear analysis
MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company that specializes in developing and commercializing innovative therapies for wound care and regenerative medicine. The company operates primarily in the advanced wound treatment market, with significant offerings such as NexoBrid, a non-surgical treatment for severe burns, and Esorex, an enzymatic debridement therapy targeting chronic wounds. MediWound is currently involved in pivotal clinical trials and has secured government contracts, particularly with BARDA, that support its expected revenue growth in the coming year.
Bull says
- ↑Reaffirmed FY2026 revenue guidance of $24–$26M, expecting H2 weight from BARDA contracts.
- ↑Q2 NexoBrid delivered record quarterly revenue; Esorex Phase III VALUE trial is actively enrolling.
- ↑T. Rowe Price holds 5% stake; analysts imply ~140% upside to price targets.
- ↑MSA with VeriCell and U.S. peak sales potential of $1.05B for Esorex.
- ↑Cash reserves of ~$36M support R&D despite $20M H1 2026 cash burn.
- ↑Positive analyst revisions and strong quality factors signal improving sentiment.
Bear says
- ↓Q2 2026 revenue plunged 46% YoY to $3.1M; gross margin shrank to 10.9%.
- ↓Net loss narrowed to $7.4M ($0.57/sh) in Q2 but remains substantial.
- ↓H1 2026 cash burn of $20M left $36M in cash, straining liquidity.
- ↓~$6M of H2 revenue tied to BARDA contracts, exposing execution risk.
- ↓Competition from Smith & Nephew and others could erode market share.
- ↓Weak earnings yield, poor profitability, and high short interest signal bearish sentiment.
Investment themes with MDWD
Drug development driving global healthcare solutions
Stocks with highest short interest
Earnings Call · Q4 2023 · Mgmt. Guidance
Transcript signals
Bull points
- In our Phase II study, EscharEx demonstrated superior results.
- The results of the head-to-head analysis are compelling and were achieved with robust statistical significance.
- Starting with the incidence of complete debridement, 63% of patients achieved complete debridement within two weeks with EscharEx versus 0% with SANTYL.
Bear points
- $5.3 million, a decrease from $11.6 million in the first quarter of 2022.
- This decrease is mainly due to the BLA approval milestone payment from Vericel received in the previous year.
- Gross profit for the quarter was $0.7 million or 13.5% of total revenue compared to the $8.2 million or 70.2% of total revenue in the first quarter of 2022.